Web27 nov 2024 · Roche did not say how much it was paying for Jecure, which gives it a preclinical portfolio of so-called NLRP3 inhibitors being developed for fighting inflammatory diseases like non-alcoholic ...
Death by inflammation: drug makers chase the master controller
Web28 nov 2024 · Jecure Therapeutics announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors. Subscribe to our e-Newsletters Stay up to date with the latest news, articles, and events. WebJecure Therapeutics Jan 2024 - Apr 2024 1 year 4 months. ... Inappropriate activation of the NLRP3 inflammasome has been implicated in multiple inflammatory and autoimmune diseases. office of disaster assistance sba
Overcoming Preclinical Safety Obstacles to Discover
Web27 nov 2024 · You can now count the biopharma giant Roche among the growing number of players fascinated by the potential of NLRP3 inhibition. Their big California subsidiary … The origins of the coming wave of NLRP3 inhibitors can be traced back to Pfizer’s work in the late 1990s, when the company was hunting for compounds that could block the secretion of IL-1. Through a phenotypic screening strategy, it identified a series of anti-inflammatory compounds with this effect, … Visualizza altro IFM Tre advanced its systemic NLRP3 inhibitor IFM-2427into a phase I trial in healthy volunteers, just days before Novartis announced that it was acquiring this portfolio. … Visualizza altro Drug developers will also have to think carefully about how to choose an optimal patient population within each indication for future … Visualizza altro Web28 nov 2024 · “The acquisition of Jecure provides a unique opportunity to bring novel NLRP3 inhibitors to patients.” Roche’s global head of Pharma Partnering James Sabry added the firm is “excited to combine Jecure’s portfolio with our discovery and development capabilities, as well as our expertise in NLRP3 biology, to potentially help people with … office of dispute resolution lubbock tx